Phenprocoumon (Liquamar)

01/01/2023 - "RCTs with phenprocoumon being absent we analysed the benefits and harms of DOACs and phenprocoumon for patients with atrial fibrillation (AF) in a real-world setting. "
01/01/2023 - "Using the German Pharmacoepidemiological Research Database (GePaRD; claims data of ~20% of the German population), we identified persons with a first dispensing of phenprocoumon or a DOAC and a diagnosis of non-valvular atrial fibrillation between August 2011 and December 2019. "
11/01/2021 - "Here, the case of a 92-year-old female patient, who was diagnosed with atrial fibrillation and treated with phenprocoumon (Marcumar®), is reported. "
01/01/2018 - "There is little evidence documenting effectiveness and safety of NOACs compared with phenprocoumon in atrial fibrillation (AF). "
01/01/2015 - "He was started on phenprocoumon due to atrial fibrillation and systolic dysfunction. "

01/15/2012 - "In conclusion, oral anticoagulation with phenprocoumon represents a safe and effective treatment in clinically stable patients with obstructive thrombosis of bioprosthetic aortic valves, thus obviating repeat valve surgery or thrombolysis."
01/01/2019 - "Because of the idiopathic character of that thrombosis, the patient remained on long-term anticoagulation with phenprocoumon. "
09/01/2012 - "In fresh thrombi, anticoagulation with phenprocoumon results in thrombus resolution in most patients."
01/15/2012 - "We therefore evaluated oral anticoagulation with phenprocoumon as an alternative treatment for obstructive thrombosis of bioprosthetic valves. "
01/01/2012 - "In April 2009, the computed tomography (CT) scan revealed a portassociated thrombosis with cava superior syndrome, despite treatment with phenprocoumon and an international normalized ratio (INR) of 3.75 at the time of the event. "

11/01/2018 - "Stroke patients were categorized as follows: Group1, phenprocoumon intake, international normalized ratio (INR) ≥1.7 on admission, no thrombolysis; Group2, INR < 1.7 on admission, thrombolysis; and Group3, INR < 1.7, no thrombolysis. "
01/01/2020 - "Phenprocoumon may be preferable to DOAC treatment for the prevention of strokes in AF in a real-world population cared for in ambulatory care."
01/01/2009 - "Pharmacogenetic testing for guiding de novo phenprocoumon therapy in stroke patients."
01/01/2020 - "This study provides a comprehensive view of the stroke and bleeding risks associated with phenprocoumon and DOAC use in Germany. "
01/01/2020 - "This study aims at comparing the risk of stroke and bleeding in phenprocoumon- and DOAC-treated patients with AF in an adequately powered observational study population. "

04/01/2011 - "Because of the traumatic deep vein thrombosis phenprocoumon and clopdiogrel were given for 6 months. "
01/05/2007 - "Anticoagulation treatment with phenprocoumon was started for the deep vein thrombosis. "
09/22/2006 - "Phenprocoumon was recommended to prevent deep vein thrombosis. "
09/01/2006 - "We describe a 32-year-old man with secondary antiphospholipid syndrome (APS) who received oral anticoagulation with phenprocoumon after deep vein thrombosis. "
11/01/2009 - "We present here the case of a patient with protein S deficiency, who has used COCs together with anticoagulatory therapy (Phenprocoumon) after suffering from deep venous thromboses for 4 years. "

01/01/1984 - "The model presented here is based on a phenprocoumon (PPC) standard dose calculated per kg body weight by adapting it to experimentally obtained mean values of biological half-life (t1/2) and relative volume of distribution (Vrel) of PPC taken from the literature. "
04/01/1994 - "The pharmacokinetics of phenprocoumon was studied in 24 healthy volunteers between the ages of 23 and 28 years and a mean body weight of 72 kg by intraindividual comparison of the plasma level after i.v. and oral administration of 9 mg phenprocoumon (PPC) or by the evaluation of the total plasma clearance of PPC by simultaneous measurement of the urinary excretion and of the plasma concentration after the administration of 9 mg PPC. "
03/01/1976 - "The first one was the control group without any manipulation, the second received an one-stage X-irradiation with 2500 R SD directed to the tail tumor, the third was treated with an oral dose of Phenprocoumon which was added to the daily drinking quantity (0.1 mg/kg body weight), and the fourth group was given an one-stage X-irradiation together with the oral Phenprocoumon treatment. "
02/01/2009 - "Consecutive patients receiving enoxaparin at a dosage of 1 mg/kg body weight/12 hours for temporary interruption of phenprocoumon were prospectively enrolled to the study. "
08/01/2010 - "Phenprocoumon was stopped 7 days before surgery and after reaching an INR less than 2,0 all patients received enoxaparin in a half-therapeutic dose (1 x 1 mg / kg body weight (bw)/day) until the day before surgery. "